

**"EXPRESS MAIL CERTIFICATE"**  
**"EXPRESS MAIL" MAILING LABEL NUMBER EV332944282US**  
**DATE OF DEPOSIT: April 13, 2004**

Attorney Docket No. P31902C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant:	Buckingham et al.	April 13, 2004
Serial No.:	Not Yet Assigned	Group Art Unit: Not Yet Assigned
Filed:	Herewith	Examiner: Not Yet Assigned
For:	USE OF THIAZOLIDINEDIONES FOR THE TREATMENT OF HYPERGLYCAEMIA	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER  
37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited reference is enclosed, except for those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Kathryn L. Sieburth  
Attorney for Applicants  
Registration No. 40,072

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5012  
Facsimile (610) 270-5090

N:\kls\cases\p31902c3\IDS Letter.doc

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31902C3	SERIAL NO. Not Yet Assigned
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Buckingham et al.	
		FILING DATE Herewith	GROUP Not Yet Assigned

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		5,708,012	1/13/98	Jerrold M. Olefsky	514	337	

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. <b>P31902C3</b>	PRED. SERIAL NO. <b>10/154,725</b>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT <b>Buckingham et al.</b>	
		PRED. FILING DATE <b>May 24, 2002</b>	PRED. GROUP ART UNIT <b>1614</b>

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,002,953	3/26/91	Hindley	514	275	
	6,288,095	9/11/01	Hindley et al.	514	367	
	20020006939	1/17/02	Buckingham et al.	514	340	
	5,194,443	3/16/93	Hindley	514	367	
	5,232,925	8/3/93	Hindley	514	272	
	5,260,445	11/9/93	Hindley	548	183	
	5,521,201	5/28/96	Hindley et al.	514	342	
	5,646,169	7/8/97	Hindley et al.	514	369	
	5,741,803	4/21/98	Pool et al.	514	342	
	5,756,525	5/26/98	Hindley et al.	514	364	
	5,910,592	6/8/99	Pool et al.	546	269.7	
	6,166,049	12/26/00	S.A. Smith	514	352	
	5,972,944	10/26/99	Antonucci et al.	514	252	
	20030069283	4/10/03	Buckingham et al.	514	342	
	20030109552	6/12/03	R.E. Buckingham	514	342	
	20020049240	4/25/02	Hindley et al.	514	369	

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 00/27341	5/18/00	PCT				
	WO 98/55122	12/10/98	PCT				
	WO 98/02159	1/22/98	PCT				
	WO 97/05875	2/20/97	PCT				
	WO 97/18811	5/29/97	PCT				
	0 796 618	9/24/97	EP				
	0 419 035	3/27/91	EP				
	0 419 035 B1	2/15/95	EP				
	WO 94/25026	11/10/94	PCT				
	WO 95/07694	3/23/95	PCT				
	WO 97/25042	7/17/97	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	"R&D Focus Drug News", Dialog File Supplier: File 445 R&D Focus, Accession Numbers 16402 and 14818, 05 May 1997 – 10 March 1997. XP002082979.
	"Rosiglitazone SmithKline Beecham Clinical Data", STN File Supplier: Drugnl: Accession Number 1391 & R&D Focus News, 27 April 1998, XP002082989.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31902C3	PRED. SERIAL NO. 10/154,725
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Buckingham et al.	
		PRED. FILING DATE May 24, 2002	PRED. GROUP ART UNIT 1614

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,478,852	12/1995	Olefsky et al.	514	369	

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes   No
WO 94/05659	3/1994	PCT			
0 306 228 A1	3/1989	EP			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	"The Pink Sheet", Dialog File Supplier: File 187: F-D-C Reports, Accession Number 600160005, Vol. 60(16), 20 April 1998. XP002082978.
	"Physician's Desk Reference 54th Edition, 2000, Medical Economics Company, pages 2980-2984, citation based on labeling dated June 15, 1999.
	National Institute for Clinical Excellence, Appraisal Consultation Document, D. Barnett, Review: "The Clinical Effectiveness and Cost Effectiveness of Glitazones for the Treatment of Type 2 Diabetes", January 2003.
	Kumar et al. "Troglitazone, an Insulin Action Enhancer, Improves Metabolic Control in NIDMM Patients". <i>Diabetologia</i> , <u>39</u> (6): 701-709 (1996).
	Berger et al., "Thiazolidinediones Produce a Conformational Change in Peroxisomal Proliferator-Activated Receptor Gamma: Binding and Activation Correlate with Antidiabetic Actions in db/db Mice". <i>Endocrinology</i> , <u>137</u> (10): 4189-4195 (1996).
	Florez et al., "Pasos hacia la prevencion primaria de la diabetes mellitus tipo II. Algunas consideraciones epidemiologicas". <i>Invest. Clin.</i> , <u>38</u> (1): 39-52.
	Grossman et al., "Mechanisms and Clinical Effects of Thiazolidinediones". <i>Expert Opin. Invest. Drug</i> , <u>6</u> (8): 1025-1040 (1997). (Abstract)
	Chang et al., "The Hypoglycemic effect of Ciglitazone in Obese, Hyperglycemic Animal Models". <i>Prog. Clin. Biol. Res.</i> , <u>265</u> : 177-192 (1988) (Abstract).
	Stevenson et al., "Actions of Novel Antidiabetic Agent Englitazone in Hyperglycemic Hyperinsulinemic ob/ob Mice". <i>Diabetes</i> , <u>39</u> (10): 1218-1227 (1990) (Abstract).
	Sreenan et al., "Prevention of Hyperglycemia in the Zucker Diabetic Fatty Rat by Treatment with Metformin or Troglitazone". <i>Am. J. Physiol.</i> , <u>271</u> (4 Pt 1): E742-E747 (1996) (Abstract).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

N:\kls\cases\p31902c3\PTO 1449 transferred refs form.doc